Image-01 (Image 01)
Levetiracetam
Product Images NDC 71093-144
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71093-144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Aci Healthcare Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image-02 (Levetiracetam Fig1)
Image-01 (Levetiracetam Fig2)
The text describes Figure 2 showing the Responder Rate in Study 2 with a comparison of placebo versus two different dosages of Levetiracetam. The figure shows the percentage of patients who had a 250% reduction from baseline. One dosage of Levetiracetam resulted in a statistically significant difference from placebo.*
Image-03 (Levetiracetam Fig3)
The Figure 3 shows the Responder Rate, with more than 50% of reduction from baseline in Study 3. The percentage of responder rate for placebo (N=104) was 14.4%, whereas for Levetiracetam 3000 mg/day (N=180) was 45%, and it's statistically significant versus placebo. There is a graphical representation of data with bars and percentages.*
Image-04 (Levetiracetam Fig4)
The figure shows the Responder Rate in Study 4 with a 50% Reduction from Baseline. The placebo group had a Responder Rate of 19.6% while the group using Levetiracetam had a Responder Rate of 44.6%. The data indicates that the Levetiracetam group had a statistically significant improvement in Responder Rate compared to the placebo group.*
Image-05 (Levetiracetam Fig5)
The text describes Figure 5 which shows the Responder Rate for all patients aged 1 month to less than 4 years, and their reduction from baseline in Study 5. The figure displays a bar graph that compares the percentage of patients who responded to treatment after being given Placebo and Levetiracetam. The graph shows that Levetiracetam had a statistically significant higher responder rate compared to Placebo.*
Image-06 (Levetiracetam Fig6)
The figure shows the responder rate in PGTC seizure frequency per week in Study 7 with a 250% reduction from baseline. The percentage of patients who responded to the treatment is shown on the y-axis while the treatment groups (placebo and levetiracetam) are shown on the x-axis. The results indicate that 72.2% of patients in the levetiracetam group had a significant reduction in PGTC seizure frequency, which was statistically significant compared to the placebo group. 45.2% of patients in the placebo group had a reduction in seizure frequency. 9% of patients did not respond to the treatment.*
Image-8 (Levetiracetam Label)
Levetiracetam is a medication available in the form of an oral solution in the United States Pharmacopeia (USP). Further details about the medication are not available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
